On May 21, Denver-based Davita Inc. (NYSE:DVA) announced it was buying HealthCare Partners (HCP) for $4.42 billion. The next day its stock dropped more than 5% on the news. Investors might not have liked what they heard, but I certainly did. I first came across Davita when I chronicled its exceptionally democratic workplace back in April 2010. Now that it's diversifying its revenue streams, the future looks brighter than ever. Trading within roughly 7% of its all-time high, you're not getting a bargain by any means. However, you are buying growth at a reasonable price.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

HealthCare Partners
Located in Torrance, California, HCP is the largest owner/operator of physician practices in the US. HCP makes money by providing health care at lower costs and better outcomes. It's the healthcare model of the future that has patients, payors and physicians all on the same page. Davita and HCP made this deal to speed the move to flat-fee primary care practices. Unfortunately, it took the parties 15 years to consummate a deal. I say this only half-joking. Apparently, Kent Thiry, CEO of Davita and Dr. Robert Margolis, CEO of HCP, originally met in 1997, but were unable to come to terms.

Thanks to the "medical loss ratio" requirement in Obamacare, which mandates health insurers spend at least 80% of the premiums collected for medical services or activities that benefit a patient's health; health insurers who don't, must rebate those misspent premiums to the consumer. HCP is already living within this system as it receives capitated payments per enrolled patient and must deliver medical care below those rates in order to profit from the relationship. By putting fewer restrictions on the medical care, including the number of visits, it's able to reduce the cost of care. Operating in California, Nevada and Florida, its relationship with hospitals, physicians and payors is top-notch.

SEE: Investing In The Healthcare Sector

Financial Implications
Davita paid $3.66 billion in cash and 9.38 million shares of stock. That's 8.4 times EBITDA. However, due to the legal structure of HCP, it actually costs just 7.2 times EBITDA. How's that possible? It was a limited liability company. As a result, Davita gets to step up the basis for a majority of what it paid and amortize for tax purposes most of that cost. As long as the combined entities achieve annual pretax profits of $100 million, it could save as much as $900 million on the deal.

The combined entities had 2011 revenues of $9.4 billion and EBITDA profits of $1.92 billion, so it's likely to achieve the entire savings. In the short-term, the only negative I see is that it's adding $3.8 billion in new debt, almost doubling its current amount. On the bright side, it was able to use its shares to pay for 17% of the deal. The transaction assigned a value of $81 a share, which is within 10% of its all-time high of $90.42. That's how you use share dilution. Now it can use its free cash to buy back shares should investors push it below $80.

Davita and Peers

Company

EV/EBITDA

Davita

7.78

Quest Diagnostics (NYSE:DGX)

7.61

Laboratory Corporation of America (NYSE:LH)

8.00

HCA Holdings (NYSE:HCA)

6.36

Intangibles

There are two that come to mind. The first involves the consistency of its stock. In the past decade, its annualized total return was 18.27%, considerably higher than either the S&P 500 or the medical care sector. More impressive still is the fact it only had two down years out of 10 with 2008 its worst at about a negative 12%. When you consider the index was off by 37% in 2008, you begin to appreciate how safe an investment it's been for long-term shareholders. The second intangible is Warren Buffett. Berkshire Hathaway (NYSE:BRK.B) owns six million shares or approximately 6.4% of its stock. In the first quarter Berkshire Hathaway picked up 3.3 million shares, more than doubling its stake in the company. I realize he's handed off most of the stock buying to Todd Combs and Ted Weschler, but his mere presence attracts additional investor attention. That can only be good for its stock.

SEE: Think Like Warren Buffett

Bottom Line

Don't be put off by the additional debt or the price of its stock. This is an excellent company that's about to get even better. Don't be shy.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Will Ashworth did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Clinical Trials

    Learn more about the BioShares Biotechnology Clinical Trials Fund, a new and innovative fund focusing on breakthroughs in the health industry.
  2. Mutual Funds & ETFs

    ETF Analysis: First Trust NYSE Arca Biotech

    Learn more about the First Trust NYSE Arca Biotechnology Fund, a highly rated exchange-traded fund in the biotech space.
  3. Mutual Funds & ETFs

    ETF Analysis: Direxion Daily Healthcare Bull 3X

    Learn about the Direxion Daily Healthcare Bull. This is a leveraged ETF that tracks the health care sector, which is a leader in this bull market.
  4. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  5. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  6. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  7. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  8. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  9. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  10. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Medical Identity Theft

    Stealing another person’s health insurance information so that ...
  3. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  4. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  5. Case Management

    Planning, processing and monitoring the healthcare services given ...
  6. Medical Patent

    A legal protection against market competition that a government ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!